Clinical Trial Update: IL-17 Blockade to Decrease irAEs (REPLAY) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial (REPLAY) is evaluating an IL-17 blockade approach to reduce immune-related adverse events in patients with metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Investigational IL-17 blockade (REPLAY)

Snippet

Sponsor: Duke University | Conditions: Metastatic Melanoma | Phase 1 | Status: NOT_YET_RECRUITING